🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Germany / NCT07553676
Recruiting Observational

Multicenter Study for Diagnostic Validation of a Laboratory Test for the Diagnosis of Endometriosis

NCT07553676 · tracked via the Priya Life Science Germany tracker
Sponsor
Diamens FlexCo
Phase
Observational
Started
2026-05-06
Last updated
2026-05-11

Condition(s) studied

Endometriosis

Study summary

Endometriosis affects at least 1 in 10 women worldwide and is associated with a diagnostic delay of 5-10 years. Currently, definitive diagnosis requires invasive laparoscopy, which is costly and burdensome for patients.

This multicenter diagnostic validation study investigates a non-invasive laboratory test for the diagnosis of endometriosis based on the analysis of biomarkers from menstrual blood samples.

Study Objective:

The primary objective is to evaluate the diagnostic accuracy of a laboratory protocol for biomarker analysis from menstrual blood samples. Performance metrics including Area Under the Curve (AUC), sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) will be assessed by comparing women with confirmed endometriosis to confirmed controls.

Study Design:

This is a prospective multicenter diagnostic study. Menstrual blood samples are self-collected by participants.

Participants:

A total of 200 menstruating women aged 14-49 years will be enrolled across study sites. Participants are allocated to one of two cohorts.

Study Sites:

The study is conducted at multiple gynecological centers in Austria and Germany, with planned expansion to additional sites.

Sponsor: Diamens FlexCo, Linz, Austria

Expected Study Duration: 3 years

Eligibility

Sex
FEMALE
Min age
14 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion criteria: * Women aged 14 to 49 * Menstruating * Endometriosis group * Histologically confirmed endometriosis * Imaging-verified endometriosis * Laparoscopy-negative group: \- Laparoscopy with no evidence of endometriosis * Imaging-negative group: * Healthy women (no symptoms of endometriosis) * Imaging shows no evidence of endometriosis Exclusion criteria: * Amenorrhea * Pregnancy * Oncological diseases * Use of GnRH agonists or antagonists

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Gynlounge Linz Austria Recruiting
Institut für Gynäkologie, Geburtshilfe und Gyn. Endokrinologie am Kepler Universitätsklinikum Linz Austria Recruiting
Gynäkologie und Geburtshilfe am Landesklinikum Melk Melk Austria Recruiting
Kinder- und Jugendgynäkologie Villa Medica Medizinisches Kompetenzzentrum GmbH Mödling Austria Recruiting
Wahlarztordination Puschacher Pöggstall Austria Recruiting
Krankenhaus der Barmherzigen Brüder Wien Vienna Austria Recruiting
Frauenklinik Städtisches Klinikum Karlsruhe Karlsruhe Germany Recruiting
Klinik für Frauenheilkunde und Geburtshilfe Barmherzige Brüder Klinik St. Hedwig Regensburg Germany Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07553676 on ClinicalTrials.gov ↗ ← All trials in Germany